Controlled trial of ornithine alpha ketoglutarate (OAKG) in patients with stroke.
A double blind controlled trial of ornithine alpha-ketoglutarate (OAKG) was carried out on 50 patients admitted to the Royal Free and Royal Northern Hospitals, London, suffering from a recent stroke. Significant improvement was found in patients treated with OAKG when examined on the fifth day of therapy as compared to their control cases. The therapy was given for 5 days. When the patients in the treated and the control groups were compared 10 days after the beginning of treatment, there were no differences between the 2 groups. Implications of these findings are discussed.
D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007656:Ketoglutaric Acids / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009952:Ornithine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
D007656:Ketoglutaric Acids; C002118:ornithine alpha-ketoglutarate; D009952:Ornithine